ArticleAnesthesia progress2025
mRNA Expression Level of IL-1β in Labial Mucosa Following Surgical Insult After Administration of Dexmedetomidine.
Article in Anesthesia progress, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Dexmedetomidine (DEX) can inhibit expression levels of proinflammatory cytokines, such as interleukin 1β (IL-1β), which can cause pain and hyperalgesia. DEX has also been reported to prolong the duration and enhance the effect of local anesthesia when administered peripherally with local anesthetics. Therefore, DEX might enhance dental local anesthetics by inhibiting proinflammatory cytokine production. However, there is no current evidence supporting whether proinflammatory cytokines in the oral mucosa can be inhibited by DEX administration. Therefore, we aimed to assess whether DEX administration could inhibit proinflammatory cytokines by evaluating the IL-1β messenger RNA (mRNA) expression levels in labial mucosal tissues following surgical insult. Methods: Adult male Wistar rats (N = 15) were assigned to control, normal saline (NS), or 5 µg/kg DEX (1.25 µg DEX) administration groups. Following incision of the labial mucosa, NS or DEX solution was administered for 30 minutes. The control group underwent no surgical injury or solution administration. Samples were collected from the lower right labial mucosa from rats in the control and experimental groups and analyzed using real-time reverse transcription polymerase chain reaction to determine IL-1β mRNA expression levels. One-way analysis of variance was used to evaluate the effects of DEX. The Tukey post hoc test was used to compare the relative expression levels of IL-1β mRNA among the groups (control, NS, and DEX). Results: IL-1β mRNA expression in the NS group was significantly higher vs the other groups (P < .001). IL-1β mRNA expression in the DEX group was higher vs the control group but lacked significance. Conclusion: Our results showed that DEX administration can inhibit IL-1β mRNA expression in oral mucosal tissues caused by surgical insult.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.